21 CFR 522.167

§ 522.167 Betamethasone sodium phosphate and betamethasone acetate.

United States · 21 CFR — Food and Drugs · Status: effective

Cite this

Citation: 21 CFR 522.167, § 522.167 Betamethasone sodium phosphate and betamethasone acetate, United States, version 1 as recorded 2026-07-09, yourstate.us, https://yourstate.us/provision/87394
Permanent ID: ys:prov:87394@1
SHA-256: 96284846ca35edd8d249e311b24f828a453b0dba65545cef04049386782b5712

The hash is SHA-256 of this version's text, with every run of whitespace collapsed to a single space and the ends trimmed. The ID always leads back here, and checking it says whether the text you cited is still the current version.

Full text

(a) Specifications. Each milliliter (mL) of suspension contains 6 milligrams (mg) betamethasone (3.15 mg betamethasone sodium phosphate and 2.85 mg betamethasone acetate). (b) Sponsor. See No. 010797 in § 510.600(c) of this chapter. (c) Conditions of use in horses—(1) Amount. Administer 1.5 mL (9 mg total betamethasone) per joint by intra-articular injection. May be administered concurrently in up to two joints per horse. (2) Indications for use. For the control of pain and inflammation associated with osteoarthritis in horses. (3) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Legislative history

This is a federal regulation, adopted through agency rulemaking under the Administrative Procedure Act — not enacted by a recorded vote of Congress.